Why Is AHCO Stock Dropping Today? AdaptHealth Falls 36% After Q2 Earnings Miss, Guidance Cut

AdaptHealth (AHCO) shares fell 36.57% in intraday trading on Tuesday after the company reported a Q2 earnings miss and slashed its full-year revenue guidance. The results included a GAAP loss and a $144.2 million goodwill impairment charge.

What Did The Company Report?

For the second quarter of 2026, AdaptHealth reported a GAAP loss of $1.07 per share, well below the $0.17 per share profit analysts had expected. Revenue came in at $740.3 million, missing the consensus estimate of roughly $847 million.

The company cut its full-year revenue guidance to a range of $2.85 billion to $2.89 billion, down sharply from the $3.49 billion consensus — a reduction of roughly $600 million at the midpoint. The quarter included a $144.2 million goodwill impairment charge and results from discontinued operations, reflecting the company's ongoing portfolio restructuring, including the previously announced sale of its diabetes health business to Cardinal Health.

Why Did Investors React?

The guidance cut was the headline shock. A roughly $600 million reduction in the full-year revenue outlook signals that the headwinds go well beyond a single weak quarter.

The goodwill impairment — a non-cash charge that reflects a write-down of previously acquired assets — may indicate that past acquisition valuations were too optimistic, raising questions about the carrying value of remaining assets on the balance sheet. The discontinued operations add further complexity: with a portion of the business being divested, investors must now reassess what the ongoing revenue base looks like, making the already-lowered guidance harder to benchmark against the company's historical profile.

The 36.57% intraday decline erased a substantial portion of AdaptHealth's market capitalization in a single session. Volume was elevated relative to recent activity, consistent with the severity of the guidance revision.

What Comes Next?

The size of the guidance cut raises the possibility that the revenue headwinds are more structural than a one-quarter reset. The goodwill impairment may not be the last — if other reporting units face similar challenges, additional write-downs could follow.

Investors will look to management's earnings call for a detailed explanation of the assumptions behind the lowered outlook. Analyst model revisions in the coming days will determine whether the post-earnings consensus stabilizes near the new guidance range or drifts lower. The regular session close will show whether institutional investors view the sell-off as a rational repricing of diminished growth expectations.